Navigation Links
Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
Date:3/31/2011

WALTHAM, Mass., March 31, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced 11 posters on entinostat, an oral, highly selective, class I histone deacetylase (HDAC) inhibitor, will be presented at the 102nd Annual American Association for Cancer Research meeting April 2 to April 6 in Orlando, FL.

"The breadth of exciting data being presented at AACR provides additional insight into the opportunities for Syndax to build out our entinostat development program," said Joanna Horobin, president and chief executive officer of Syndax. "The AACR presentations add to the growing body of evidence supporting the potential for entinostat in solid tumors including the promising results with entinostat in combination with Tarceva® in advanced non-small-cell lung cancer which were presented at the end of last year. Recently we completed our randomized, placebo-controlled phase 2 clinical trial in metastatic breast cancer which will be presented at a scientific conference later this year and are aggressively moving forward with a pivotal program in this patient population." The following posters will be presented Monday, April 4: Time:

8:00 AM to 12:00 PM EDT: Presentation #:

1146 Title:

Multiple HDAC inhibitors (HDACi) reduce the expression of the oncogenic miR-17~92 cluster; a pan HDACi class effect Location:

Exhibit Hall A4-C, Poster Section 7 Time:

8:00 AM to 12:00 PM EDT: Presentation #:

1792 Title:

Selective class I HDAC inhibitor SNDX-275 enhances anti-tumor survivin vaccine therapy by suppressing regulatory T cells in a model of prostate cancer Location:

Exhibit Hall A4-C, Poster Section 32 Time:

1:00 to 5:00 PM EDT: Presentation #:

2018 Title:

Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model Location:

Exhibit Hall A4-C, Poster Section 3 Time:

1:00 to 5:00 PM EDT: Presentation #:

2572 Title:

The histone deacetylase inhibitors (HDACIs) vorinostat and entinostat interact synergistically with the Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 to induce apoptosis in imatininb mesylate (IM)-sensitive and -resistant CML and ALL cells Location:

Exhibit Hall A4-C, Poster Session 27 Time:

1:00 to 5:00 PM EDT: Presentation #:

2614 Title:

Inhibition of class I histone deacetylases attenuates anthracycline induced activation of the ATM pathway Location:

Exhibit Hall A4-C, Poster Session 29 Time:

1:00 to 5:00 PM EDT: Presentation #:

2618 Title:

DNMT1 as a marker of differential sensitivities to epigenetic therapy of a Kras mutant and Kras wild type human non small cell lung cancer cell line Location:

Exhibit Hall A4-C, Poster Session 29 Time:

1:00 to 5:00 PM EDT: Presentation #:

2633 Title:

Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration Location:

Exhibit Hall A4-C, Poster Session 29 The following posters will be presented Tuesday, April 5: Time:

8:00 AM to 12:00 PM EDT: Presentation #:

3519 Title:

Histone deacetylase inhibitors upregulates thymidine phosphorylase gene and protein expression and synergize with capecitabine in breast cancer cells Location:

Exhibit Hall A4-C, Poster Session 26 Time:

1:00 to 5:00 PM EDT: Presentation #:

LB-411 Title:

A phase II study of combination epigenetic therapy in advanced non-small cell lung cancer Location:

Exhibit Hall A4-C, Poster Session 40 The following posters will be presented Wednesday, April 6: Time:

8:00 AM to 12:00 PM EDT: Presentation #:

5335 Title:

The histone deacetylase inhibitor MS-275 sensitizes osteosarcoma cells and osteosarcoma lung metastases to FasL-induced cell death by the downregulation c-FLIP Location:

Exhibit Hall A4-C, Poster Session 25 Time:

8:00 AM to 12:00 PM EDT: Presentation #:

5048 Title:

Targeting regulators of Chk1 to enhance cytotoxic efficacy of HDAC inhibitors Location:

Exhibit Hall A4-C, Poster Session 12 About Entinostat Entinostat is an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every-other-week dosing. Entinostat is being studied in advanced breast cancer in combination with aromatase inhibitors and recently completed a randomized, placebo-controlled phase 2 trial in this patient population. The results will be presented at a scientific conference later this year. Entinostat also is being studied in various cancers including advanced non-small-cell lung cancer and advanced colorectal cancer in combination with azacitidine. At the end of last year, results were presented from a randomized phase 2 study showing a four-month survival advantage when entinostat was added to erlotinib in patients with lung cancers expressing high levels of E-cadherin. Syndax has several studies ongoing under a cooperative research and development agreement with the National Cancer Institute.

Research has shown that HDACs are involved in the expression of various genes, such as the estrogen receptor, that regulate cell growth, differentiation and apoptosis. Such genes are frequently silenced in cancer cells through the over-expression of enzymes including HDACs. HDACs are therefore recognized as promising targets for cancer treatment. Further, studies have demonstrated that HDAC inhibition can significantly enhance anti-cancer activity when used in combination with a broad range of anti-cancer agents. The potential therefore exists to overcome tumor resistance to targeted agents.

About Syndax Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator. Syndax has worldwide rights to develop and commercialize entinostat and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. For more information please visit www.syndax.com.

Contact Information
E. Blair Schoeb
Syndax Pharmaceuticals, Inc
Tel: 908-277-0386
bschoeb@syndax.com


'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
2. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
3. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
4. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
5. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
6. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
7. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
8. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
9. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology:
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
Breaking Medicine News(10 mins):